• Yasuhide Miyoshi, Masahiro Furuya, Jun-ichi Teranishi, Kazumi Noguchi, Hiroji Uemura, Yumiko Yokomizo, Shinpei Sugiura, and Yoshinobu Kubota.
• Department of Urology, Yokohama City Medical Center, Yokohama, Japan. miyoyasu@med.yokohamacu. ac.jp.
• Urol J. 2014 May 1;11(3):1609-14.

PurposeIn the present study, we compared 12- with 16-core biopsy in patients with prostate- specific antigen (PSA) levels of 4.0-20.0 ng/mL.Materials And MethodsBetween 2003 and 2010, 332 patients whose serum PSA level was between 4.0 and 20.0 ng/mL underwent initial transrectal ultrasound (TRUS)-guided needle biopsy. Of those patients, 195 underwent 12-core biopsy and 137 underwent 16-core biopsy.ResultsIn the 12-core prostate biopsy group, 66 (33.8%) patients were found to have prostate cancer. On the other hand, in the 16-core prostate biopsy group of 137 patients, 61 (44.5%) were found to have prostate cancer. Among all patients, the prostate cancer detection rate was slightly higher in the 16-core biopsy group than in the 12-core biopsy group. Moreover, in patients with prostate volume > 30 mL or PSA density (PSAD) < 0.2, the prostate cancer detection rate was significantly higher in the 16-core biopsy group than in the 12-core biopsy group. There was no significant difference in pathological tumor grade, indolent cancer probability, or biopsy complication rate between the two groups.ConclusionIn order to detect prostate cancer, 16-core prostate biopsy is safe and feasible for Japanese patients with serum PSA level of 4.0-20.0 ng/mL.

12 keywords...

hide…